| 1 | Cancer | 1.4% | |
| 2 | Study | 1.35% | |
| 3 | Case | 0.99% | |
| 4 | Report | 0.88% | |
| 5 | Risk | 0.82% | |
| 6 | Patients | 0.8% | |
| 7 | Disease | 0.74% | |
| 8 | New | 0.63% | |
| 9 | HIV | 0.6% | |
| 10 | Health | 0.58% | |
| 11 | May | 0.55% | |
| 12 | ASCO | 0.49% | |
| 13 | Treatment | 0.41% | |
| 14 | Therapy | 0.41% | |
| 15 | Cardiovascular | 0.38% | |
| 16 | AI | 0.36% | |
| 17 | According | 0.33% | |
| 18 | Linked | 0.33% | |
| 19 | Review | 0.3% | |
| 20 | Blood | 0.27% | |
| 21 | Management | 0.27% | |
| 22 | Heart | 0.27% | |
| 23 | Vaccine | 0.27% | |
| 24 | Metastatic | 0.27% | |
| 25 | Breast | 0.27% | |
| 26 | Syndrome | 0.27% | |
| 27 | Use | 0.25% | |
| 28 | Renal | 0.25% | |
| 29 | Patient | 0.25% | |
| 30 | Alzheimer’s | 0.25% | |
| 31 | Outcomes | 0.25% | |
| 32 | US | 0.22% | |
| 33 | Prostate | 0.22% | |
| 34 | Brain | 0.22% | |
| 35 | Liver | 0.22% | |
| 36 | Phase | 0.22% | |
| 37 | Metabolic | 0.22% | |
| 38 | U.S. | 0.22% | |
| 39 | Reveals | 0.22% | |
| 40 | Clinical | 0.22% | |
| 41 | Carcinoma | 0.22% | |
| 42 | Immune | 0.22% | |
| 43 | Role | 0.19% | |
| 44 | Rare | 0.19% | |
| 45 | Potential | 0.19% | |
| 46 | Chronic | 0.19% | |
| 47 | Dementia | 0.19% | |
| 48 | Gene | 0.19% | |
| 49 | Africa | 0.19% | |
| 50 | Research | 0.19% | |
|
는 분류, 데이터 기준으로 의 기사에서 의 고유명사 데이터를 통해 생성되었습니다.
|
|||
Phase 2 Data on Rilzabrutinib as Rescue Medication for Asthma, with William Busse, MD
HCPLive
2025-05-30 05:06:28
CMSC Poster Gives Demographic Insights for Phase 3 PERSEUS Study of Tolebrutinib
NeurologyLive
2025-05-29 19:07:09